Tailored Treatment of Permanent Atrial Fibrillation

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Atrial Fibrillation
Interventions
PROCEDURE

Medtronic Cardiac Ablation System

Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.

DRUG

Class I or III Antiarrhythmic Medications

Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.

Trial Locations (24)

14642

University of Rochester, Rochester

16502

Consultants in Cardiovascular Diseases, Erie

20912

Washington Adventist Hospital, Takoma Park

21287

Johns Hopkins Hospital, Baltimore

23507

Sentara Cardiovascular Research Institute, Norfolk

27157

Wake Forest University, Winston-Salem

30308

Emory Crawford Long Hospital, Atlanta

30309

Piedmont Hospital, Atlanta

32224

Mayo Clinic Jacksonville, Jacksonville

43210

The Ohio State University, Columbus

46202

Krannert Institute of Cardiology, Indianapolis

48109

University of Michigan, Ann Arbor

49503

Spectrum Health Research Department, Grand Rapids

50309

Iowa Heart Center, Des Moines

52803

Genesis Medical Center, Davenport

60637

University of Chicago, Chicago

77030

Texas Heart Institute at St. Luke's Episcopal, Houston

78756

Austin Heart, Austin

85251

Arizona Arrhythmia Research Center, Scottsdale

90095

UCLA Cardiac Arrhythmia Center, Los Angeles

02114

Massachusetts General Hospital Cardiac Arrhythmia, Boston

02115

Brigham and Women's Hospital, Boston

01805

Lahey Clinic, Burlington

Unknown

St. Antonius Ziekenhuis, Nieuwegein

All Listed Sponsors
lead

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

NCT00514735 - Tailored Treatment of Permanent Atrial Fibrillation | Biotech Hunter | Biotech Hunter